Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.17 and traded as low as $3.27. Cryo-Cell International shares last traded at $3.34, with a volume of 12,627 shares changing hands.

Wall Street Analyst Weigh In

Separately, Maxim Group cut Cryo-Cell International from a “buy” rating to a “hold” rating in a research note on Monday, October 20th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Cryo-Cell International currently has a consensus rating of “Hold” and an average price target of $8.50.

Cryo-Cell International Stock Down 1.8%

The company has a market cap of $26.92 million, a PE ratio of -47.71 and a beta of 0.59. The business has a 50-day simple moving average of $3.56 and a 200-day simple moving average of $4.17.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. Institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.